China CAS:107724-20-9 Manufacturer

We've been experienced manufacturer. Wining the majority on the crucial certifications of its market for CAS:107724-20-9, Top quality and competitive rates make our products and solutions appreciate a higher name all around the word.
CAS:107724-20-9, Our products are very popular in the word, like South American, Africa, Asia and so on. Companies to "create first-class products" as the goal, and strive to provide customers with high quality products, provide high-quality after-sales service and technical support, and customer mutual benefit, create a better career and future!

Hot Products

  • Finasteride

    Finasteride

    Finasteride has EP, USP, CP, IP, JP specifications. CEP available, FDA, PMDA and GMP approved.

    CAS:98319-26-7

  • Dutasteride

    Dutasteride

    Dutasteride has EP, USP, CP, IP, JP specification. CEP and FDA available.

    CAS:164656-23-9

  • Nintedanib Esylate

    Nintedanib Esylate

    Nintedanib Esylate has in-house specification. DMF available.

    CAS:656247-18-6

  • Gestodene

    Gestodene

    Gestodene has CP and EP specification. DMF, GMP available.

    CAS:60282-87-3

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide

    N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide

    N-tert-butyl-3-oxo-4-aza-5α-androst-17β-carboxamide is an intermediate of Dutasteride.

    CAS:98319-24-5

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept